| |
euthyroid
|
hypothyroid
|
p
|
|---|
|
n
|
50
|
17
| |
|
Before rhGH administration
|
|
age [years]
|
12.4 ± 2.3
|
12.3 ± 2.1
|
0.94
|
|
height SDS
|
-2.60 ± 0.50
|
-2.77 ± 0.63
|
0.38
|
|
HV [cm/year]
|
3.5 ± 1.0
|
3.8 ± 0.9
|
0.14
|
|
TSH [mU/l]
|
2.22 ± 0.95
|
2.65 ± 0.92
|
0.05
|
|
FT4 [ng/dl]
|
1.33 ± 0.15
|
1.21 ± 0.11
|
0.01
|
|
IGF-I SDS
|
-2,01 ± 0.97
|
-1.99 ± 1.00
|
0.45
|
|
IGF-I/IGFBP-3
|
0.19 ± 0.07
|
0.18 ± 0.05
|
0.71
|
|
After 3-6 months of rhGH therapy
|
|
TSH [mU/l]
|
2.25 ± 0.92
|
3.71 ± 1.75
|
< 0.001
|
|
FT4 [ng/dl]
|
1.16 ± 0.10
|
1.01 ± 0.14
|
< 0.001
|
|
IGF-I SDS
|
0.37 ± 0.81
|
0.54 ± 0.81
|
0.59
|
|
IGF-I/IGFBP-3
|
0.38 ± 0.11
|
0.42 ± 0.12
|
0.36
|
|
After 1 year of rhGH therapy
|
|
TSH [mU/l]
|
2.07 ± 0.98
|
2.16 ± 0.79
|
0.54
|
|
FT4 [ng/dl]
|
1.31 ± 0.15
|
1.23 ± 0.14
|
0.11
|
|
IGF-I SDS
|
0.61 ± 0.67
|
0.83 ± 0.83
|
0.35
|
|
IGF-I/IGFBP-3
|
0.41 ± 0.09
|
0.45 ± 0.12
|
0.84
|
|
HV [cm/year]
|
10.0 ± 2.1
|
9.3 ± 2.0
|
0.23
|
|
ΔHV [cm/year]
|
6.5 ± 2.3
|
5.4 ± 2.1
|
0.01
|
|
ΔHV [%]
|
213 ± 118
|
154 ± 85
|
0.05
|
